Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-ressistant schizophrenia

Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-ressistant schizophrenia

A recent umbrella review suggested that pneumonia is the most robust of the life-threatening medical events associated with antipsychotic use. More importantly, the literature suggests that clozapine appears to be more strongly associated with pneumonia than are other antipsychotics. However, clozap...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta psychiatrica Scandinavica 2020-05
Hauptverfasser: Villasante-Tezanos, A G, Rohde, C, Nielsen, J, de Leon, J
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title Acta psychiatrica Scandinavica
container_volume
creator Villasante-Tezanos, A G
Rohde, C
Nielsen, J
de Leon, J
description A recent umbrella review suggested that pneumonia is the most robust of the life-threatening medical events associated with antipsychotic use. More importantly, the literature suggests that clozapine appears to be more strongly associated with pneumonia than are other antipsychotics. However, clozapine is mainly prescribed in patients with treatment-resistant schizophrenia (TRS); therefore, the risk of pneumonia in clozapine patients is likely to be the result of the combined effects of TRS and clozapine. No published study has explored the relative contributions of these two factors.
doi_str_mv 10.1111/acps.13184
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_32415875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32415875</sourcerecordid><originalsourceid>FETCH-pubmed_primary_324158753</originalsourceid><addsrcrecordid>eNqFjrtqw0AQRZeA8bvJB4T5ATm7lmSJtCYhpYv0ZiyN0SbS7rIzQra_PoIkkM63uc2Bc5R6NHpjxj1jFXhjUlNmD2pudlonOsuKmVowf2qtc6PLqZql28zkZZHP1XBw1HfeWYRo-esFMIToL7ZDofYK3lEijY01WIa6JxAPVetvGKwjQFeDDP6H4H-IRELpyEkSidmyoBPgqrE3H5pIo22lJmdsmda_v1RPb68f-_ck9KeO6mOIY0K8Hv9K07vAN9-IUFU</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-ressistant schizophrenia</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Villasante-Tezanos, A G ; Rohde, C ; Nielsen, J ; de Leon, J</creator><creatorcontrib>Villasante-Tezanos, A G ; Rohde, C ; Nielsen, J ; de Leon, J</creatorcontrib><description>A recent umbrella review suggested that pneumonia is the most robust of the life-threatening medical events associated with antipsychotic use. More importantly, the literature suggests that clozapine appears to be more strongly associated with pneumonia than are other antipsychotics. However, clozapine is mainly prescribed in patients with treatment-resistant schizophrenia (TRS); therefore, the risk of pneumonia in clozapine patients is likely to be the result of the combined effects of TRS and clozapine. No published study has explored the relative contributions of these two factors.</description><identifier>EISSN: 1600-0447</identifier><identifier>DOI: 10.1111/acps.13184</identifier><identifier>PMID: 32415875</identifier><language>eng</language><publisher>United States</publisher><ispartof>Acta psychiatrica Scandinavica, 2020-05</ispartof><rights>This article is protected by copyright. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32415875$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Villasante-Tezanos, A G</creatorcontrib><creatorcontrib>Rohde, C</creatorcontrib><creatorcontrib>Nielsen, J</creatorcontrib><creatorcontrib>de Leon, J</creatorcontrib><title>Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-ressistant schizophrenia</title><title>Acta psychiatrica Scandinavica</title><addtitle>Acta Psychiatr Scand</addtitle><description>A recent umbrella review suggested that pneumonia is the most robust of the life-threatening medical events associated with antipsychotic use. More importantly, the literature suggests that clozapine appears to be more strongly associated with pneumonia than are other antipsychotics. However, clozapine is mainly prescribed in patients with treatment-resistant schizophrenia (TRS); therefore, the risk of pneumonia in clozapine patients is likely to be the result of the combined effects of TRS and clozapine. No published study has explored the relative contributions of these two factors.</description><issn>1600-0447</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFjrtqw0AQRZeA8bvJB4T5ATm7lmSJtCYhpYv0ZiyN0SbS7rIzQra_PoIkkM63uc2Bc5R6NHpjxj1jFXhjUlNmD2pudlonOsuKmVowf2qtc6PLqZql28zkZZHP1XBw1HfeWYRo-esFMIToL7ZDofYK3lEijY01WIa6JxAPVetvGKwjQFeDDP6H4H-IRELpyEkSidmyoBPgqrE3H5pIo22lJmdsmda_v1RPb68f-_ck9KeO6mOIY0K8Hv9K07vAN9-IUFU</recordid><startdate>20200516</startdate><enddate>20200516</enddate><creator>Villasante-Tezanos, A G</creator><creator>Rohde, C</creator><creator>Nielsen, J</creator><creator>de Leon, J</creator><scope>NPM</scope></search><sort><creationdate>20200516</creationdate><title>Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-ressistant schizophrenia</title><author>Villasante-Tezanos, A G ; Rohde, C ; Nielsen, J ; de Leon, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_324158753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Villasante-Tezanos, A G</creatorcontrib><creatorcontrib>Rohde, C</creatorcontrib><creatorcontrib>Nielsen, J</creatorcontrib><creatorcontrib>de Leon, J</creatorcontrib><collection>PubMed</collection><jtitle>Acta psychiatrica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Villasante-Tezanos, A G</au><au>Rohde, C</au><au>Nielsen, J</au><au>de Leon, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-ressistant schizophrenia</atitle><jtitle>Acta psychiatrica Scandinavica</jtitle><addtitle>Acta Psychiatr Scand</addtitle><date>2020-05-16</date><risdate>2020</risdate><eissn>1600-0447</eissn><abstract>A recent umbrella review suggested that pneumonia is the most robust of the life-threatening medical events associated with antipsychotic use. More importantly, the literature suggests that clozapine appears to be more strongly associated with pneumonia than are other antipsychotics. However, clozapine is mainly prescribed in patients with treatment-resistant schizophrenia (TRS); therefore, the risk of pneumonia in clozapine patients is likely to be the result of the combined effects of TRS and clozapine. No published study has explored the relative contributions of these two factors.</abstract><cop>United States</cop><pmid>32415875</pmid><doi>10.1111/acps.13184</doi></addata></record>
fulltext fulltext
identifier EISSN: 1600-0447
ispartof Acta psychiatrica Scandinavica, 2020-05
issn 1600-0447
language eng
recordid cdi_pubmed_primary_32415875
source Wiley Online Library - AutoHoldings Journals
title Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-ressistant schizophrenia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T04%3A18%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pneumonia%20risk:%20approximately%20one-third%20is%20due%20to%20clozapine%20and%20two-thirds%20is%20due%20to%20treatment-ressistant%20schizophrenia&rft.jtitle=Acta%20psychiatrica%20Scandinavica&rft.au=Villasante-Tezanos,%20A%20G&rft.date=2020-05-16&rft.eissn=1600-0447&rft_id=info:doi/10.1111/acps.13184&rft_dat=%3Cpubmed%3E32415875%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32415875&rfr_iscdi=true